Anastrozole trials for HER2-negative Breast Cancer

All Anastrozole trials · All HER2-negative Breast Cancer trials

Phase breakdown

Recruiting trials studying Anastrozole for HER2-negative Breast Cancer

• A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer
  NCT04985266 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 49 locations
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
  NCT05524584 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
  NCT05467891 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 21 locations

Common questions

How many trials study Anastrozole for HER2-negative Breast Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.